Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gennari, 2007, Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development., Drugs Aging, 24, 361, 10.2165/00002512-200724050-00002
Palacios, 2007, The future of the new selective estrogen receptor modulators., Menopause Int, 13, 27, 10.1258/175404507780456791
Ariazi, 2006, Estrogen receptors as therapeutic targets in breast cancer., Curr Top Med Chem, 6, 181, 10.2174/156802606776173483
Vogelvang, 2006, Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women., Drugs, 66, 191, 10.2165/00003495-200666020-00005
Draper, 2003, Molecular and clinical evidence for the unique nature of individual selective estrogen receptor modulators., Clin Obstet Gynecol, 46, 265, 10.1097/00003081-200306000-00008
Baker, 2000, Selective estrogen receptor modulators in reproductive medicine and biology., Obstet Gynecol Surv, 55, S21, 10.1097/00006254-200007001-00001
Carpenter, 2006, Potential biological functions emerging from the different estrogen receptors., Ann N Y Acad Sci, 1092, 361, 10.1196/annals.1365.033
Mendelsohn, 1999, The protective effects of estrogen on the cardiovascular system., N Engl J Med, 340, 1801, 10.1056/NEJM199906103402306
Spelsberg, 1999, The actions and interactions of sex steroids and growth factors/cytokines on the skeleton., Mol Endocrinol, 13, 819, 10.1210/mend.13.6.0299
Glass, 2007, Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status., J Natl Cancer Inst, 99, 1152, 10.1093/jnci/djm059
Sato, 1998, LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo., J Pharmacol Exp Ther, 287, 1
Nilsson, 2001, Mechanisms of estrogen action., Physiol Rev, 81, 1535, 10.1152/physrev.2001.81.4.1535
Smith, 1997, Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen., Mol Endocrinol, 11, 657, 10.1210/mend.11.6.0009
Shang, 2000, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription., Cell, 103, 843, 10.1016/S0092-8674(00)00188-4
McDonnell, 1995, Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens., Mol Endocrinol, 9, 659
Shiau, 1998, The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen., Cell, 95, 927, 10.1016/S0092-8674(00)81717-1
Heery, 1997, A signature motif in transcriptional co-activators mediates binding to nuclear receptors., Nature, 387, 733, 10.1038/42750
de Gooyer, 2003, Receptor profiling and endocrine interactions of tibolone., Steroids, 68, 21, 10.1016/S0039-128X(02)00112-5
Sato, 1994, Raloxifene: a selective estrogen receptor modulator., J Bone Miner Metab, 12, S9, 10.1007/BF02383389
Jordan, 2007, Chemoprevention of breast cancer with selective oestrogen-receptor modulators., Nat Rev Cancer, 7, 46, 10.1038/nrc2048
McDonnell, 2005, The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer., Clin Cancer Res, 11, 871s, 10.1158/1078-0432.871s.11.2
Shang, 2002, Molecular determinants for the tissue specificity of SERMs., Science, 295, 2465, 10.1126/science.1068537
Katzenellenbogen, 2002, Biomedicine. Defining the “S” in SERMs., Science, 295, 2380, 10.1126/science.1070442
Bryant, 2002, Selective estrogen receptor modulators., Rev Endocr Metab Disord, 3, 231, 10.1023/A:1020076426727
Goldstein, 2006, Not all SERMs are created equal., Menopause, 13, 325, 10.1097/01.gme.0000222332.31101.42
Dickey, 1996, Development, pharmacology and clinical experience with clomiphene citrate., Hum Reprod Update, 2, 483, 10.1093/humupd/2.6.483
Beck, 2005, Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation., Cochrane Database Syst Rev, 1, CD002249
Macgregor, 1968, Further clinical experience with clomiphene citrate., Fertil Steril, 19, 616, 10.1016/S0015-0282(16)36736-X
Adashi, 1979, Gestational outcome of clomiphene-related conceptions., Fertil Steril, 31, 620, 10.1016/S0015-0282(16)44051-3
Check, 1995, The effect of consecutive cycles of clomiphene citrate therapy on endometrial thickness and echo pattern., Obstet Gynecol, 86, 341, 10.1016/0029-7844(95)00165-N
Nakamura, 1997, Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium., Fertil Steril, 67, 256, 10.1016/S0015-0282(97)81907-3
Kolibianakis, 2004, Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination., Reprod Biomed Online, 8, 115, 10.1016/S1472-6483(10)60505-6
Acharya, 1993, The effect of three anti-oestrogen drugs on cervical mucus quality and in-vitro sperm-cervical mucus interaction in ovulatory women., Hum Reprod, 8, 437, 10.1093/oxfordjournals.humrep.a138067
Tulandi, 2006, Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate., Fertil Steril, 85, 1761, 10.1016/j.fertnstert.2006.03.014
Navot, 1987, Prognostic assessment of female fecundity., Lancet, 2, 645, 10.1016/S0140-6736(87)92439-1
Jain, 2004, Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening., Fertil Steril, 82, 180, 10.1016/j.fertnstert.2003.11.045
Hendriks, 2006, The clomiphene citrate challenge test for the prediction of poor ovarian response and nonpregnancy in patients undergoing in vitro fertilization: a systematic review., Fertil Steril, 86, 807, 10.1016/j.fertnstert.2006.03.033
Vandekerckhove, 2000, Clomiphene or tamoxifen for idiopathic oligo/asthenospermia., Cochrane Database Syst Rev, 2, CD000151
Hussein, 2005, Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study., J Androl, 26, 787, 10.2164/jandrol.04180
Whitten, 2006, Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate., Fertil Steril, 86, 1664, 10.1016/j.fertnstert.2006.05.042
2003, Nolvadex (Tamoxifen Citrate) [Package Insert].
1998, Tamoxifen for early breast cancer: an overview of the randomised trials., Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4
Baum, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial., Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8
2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [comment][erratum in Lancet 2002;360:1520]., Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8
Howell, 2005, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer., Lancet, 365, 60, 10.1016/S0140-6736(04)17666-6
Thurlimann, 2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer., N Engl J Med, 353, 2747, 10.1056/NEJMoa052258
Coates, 2007, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98., J Clin Oncol, 25, 486, 10.1200/JCO.2006.08.8617
Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial., Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1
Chien, 2006, Aromatase inhibitors and bone health in women with breast cancer., J Clin Oncol, 24, 5305, 10.1200/JCO.2006.07.5382
Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study., J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371
Fisher, 2005, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study., J Natl Cancer Inst, 97, 1652, 10.1093/jnci/dji372
Powles, 1998, Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial., Lancet, 352, 98, 10.1016/S0140-6736(98)85012-5
Powles, 2007, Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial., J Natl Cancer Inst, 99, 283, 10.1093/jnci/djk050
Cuzick, 2002, First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial., Lancet, 360, 817, 10.1016/S0140-6736(02)09962-2
Cuzick, 2007, Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial., J Natl Cancer Inst, 99, 272, 10.1093/jnci/djk049
Veronesi, 1998, Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study., Lancet, 352, 93, 10.1016/S0140-6736(98)04394-3
Veronesi, 2003, Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women., J Natl Cancer Inst, 95, 160, 10.1093/jnci/95.2.160
Veronesi, 2007, Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy., J Natl Cancer Inst, 99, 727, 10.1093/jnci/djk154
Cohen, 1994, Endometrial changes with tamoxifen: comparison between tamoxifen- treated and nontreated asymptomatic, postmenopausal breast cancer patients., Gynecol Oncol, 52, 185, 10.1006/gyno.1994.1029
Cheng, 1997, Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients., Gynecol Oncol, 66, 233, 10.1006/gyno.1997.4739
Kedar, 1994, Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial., Lancet, 343, 1318, 10.1016/S0140-6736(94)92466-X
Chalas, 2005, Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial., Am J Obstet Gynecol, 192, 1230, 10.1016/j.ajog.2004.12.083
Cuzick, 2003, Overview of the main outcomes in breast-cancer prevention trials., Lancet, 361, 296, 10.1016/S0140-6736(03)12342-2
Mourits, 2001, Tamoxifen treatment and gynecologic side effects: a review., Obstet Gynecol, 97, 855
Grey, 1995, The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women., J Clin Endocrinol Metab, 80, 3191
Chang, 1996, The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study., Ann Oncol, 7, 671, 10.1093/oxfordjournals.annonc.a010715
Schapira, 1990, Serum cholesterol reduction with tamoxifen., Breast Cancer Res Treat, 17, 3, 10.1007/BF01812678
Reis, 2001, Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial., J Natl Cancer Inst, 93, 16, 10.1093/jnci/93.1.16
Love, 1992, Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer., N Engl J Med, 326, 852, 10.1056/NEJM199203263261302
Powles, 1996, Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women., J Clin Oncol, 14, 78, 10.1200/JCO.1996.14.1.78
Grey, 1995, The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women., Am J Med, 99, 636, 10.1016/S0002-9343(99)80251-4
John, 2002, Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects., Xenobiotica, 32, 699, 10.1080/00498250210143029
Buzdar, 2002, Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer., Breast Cancer Res Treat, 73, 161, 10.1023/A:1015229630260
Herrington, 2000, Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women., Arterioscler Thromb Vasc Biol, 20, 1606, 10.1161/01.ATV.20.6.1606
Herrington, 2001, Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women., J Clin Endocrinol Metab, 86, 4216, 10.1210/jcem.86.9.7799
Johnston, 2004, A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen., Cancer Chemother Pharmacol, 53, 341, 10.1007/s00280-003-0733-6
Arpino, 2003, Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer., Ann Oncol, 14, 233, 10.1093/annonc/mdg097
van Rietbergen, 2002, High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment., Clin Biomech (Bristol, Avon), 17, 81, 10.1016/S0268-0033(01)00110-3
Fleischer, 1999, Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium., J Ultrasound Med, 18, 503, 10.7863/jum.1999.18.7.503
Albertazzi, 2005, Urogenital effects of selective estrogen receptor modulators: a systematic review., Climacteric, 8, 214, 10.1080/13697130500117946
Harvey, 2006, Toremifene: an evaluation of its safety profile., Breast, 15, 142, 10.1016/j.breast.2005.09.007
Umemoto, 2006, Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene., Chem Res Toxicol, 19, 421, 10.1021/tx0503045
Kusama, 2004, Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer., Breast Cancer Res Treat, 88, 1, 10.1007/s10549-004-4384-z
Erkkola, 2005, Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women., Breast Cancer Res Treat, 93, 277, 10.1007/s10549-005-5701-x
Gong, 2006, A double-blind randomized controlled trial of toremifen therapy for mastalgia., Arch Surg, 141, 43, 10.1001/archsurg.141.1.43
Oksa, 2006, Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study., BJOG, 113, 713, 10.1111/j.1471-0528.2006.00943.x
Price, 2006, Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial., J Urol, 176, 965, 10.1016/j.juro.2006.04.011
Taneja, 2006, Toremifene—a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy., Expert Opin Investig Drugs, 15, 293, 10.1517/13543784.15.3.293
Hellmann-Blumberg, 2000, Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene., Breast Cancer Res Treat, 60, 63, 10.1023/A:1006311214152
Komi, 2004, Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women., Gynecol Endocrinol, 18, 152, 10.1080/09513590410001672197
Rutanen, 2003, Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial., Menopause, 10, 433, 10.1097/01.GME.0000063609.62485.27
Ylikorkala, 2003, Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women., Menopause, 10, 440, 10.1097/01.GME.0000063566.84134.98
Komi, 2005, Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women., Menopause, 12, 202, 10.1097/00042192-200512020-00015
Komi, 2006, Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women., J Bone Miner Metab, 24, 314, 10.1007/s00774-006-0689-9
Gennari, 2004, Ospemifene Hormos., Curr Opin Investig Drugs, 5, 448
Gradishar, 2000, Effects of high dose raloxifene in selected patients with advanced breast carcinoma., Cancer, 88, 2047, 10.1002/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E
2007, Evista (Raloxifene HCl) [Package Insert].
Draper, 1996, A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women., J Bone Miner Res, 11, 835, 10.1002/jbmr.5650110615
Delmas, 1997, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women., N Engl J Med, 337, 1641, 10.1056/NEJM199712043372301
Johnston, 2000, Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials., Arch Int Med, 160, 3444, 10.1001/archinte.160.22.3444
Jolly, 2003, Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years., Menopause, 10, 337, 10.1097/01.GME.0000058772.59606.2A
Reid, 2004, A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women., Arch Intern Med, 164, 871, 10.1001/archinte.164.8.871
Cummings, 1999, The effect of raloxifene on risk of breast cancer in postmenopausal women., JAMA, 281, 2189, 10.1001/jama.281.23.2189
Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial., JAMA, 282, 637, 10.1001/jama.282.7.637
Delmas, 2002, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial., J Clin Endocrinol Metab, 87, 3609, 10.1210/jcem.87.8.8750
Martino, 2004, Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene., J Natl Cancer Inst, 96, 1751, 10.1093/jnci/djh319
Siris, 2005, Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study., J Bone Miner Res, 20, 1514, 10.1359/JBMR.050509
Neven, 2005, Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: review of Euralox 1., Maturitas, 52, 87, 10.1016/j.maturitas.2005.03.010
Barrett-Connor, 2006, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women., N Eng J Med, 355, 125, 10.1056/NEJMoa062462
Vogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes., JAMA, 295, 2727, 10.1001/jama.295.23.joc60074
Vogel, 2007, Chemoprevention strategies 2006., Curr Treat Options Oncol, 8, 74, 10.1007/s11864-007-0019-z
Deal, 2006, Raloxifene, a selective estrogen-receptor modulator, for postmenopausal osteoporosis: a clinical update on efficacy and safety., Women’s Health, 2, 199
Johnell, 2002, Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis., J Clin Endocrinol Metab, 87, 985, 10.1210/jcem.87.3.8325
Michalska, 2006, The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis., J Clin Endocrinol Metab, 91, 870, 10.1210/jc.2004-2212
Ott, 2002, Bone histomorphometric and biochemical marker results of a two-year placebo controlled trial of raloxifene in postmenopausal women., J Bone Miner Res, 17, 341, 10.1359/jbmr.2002.17.2.341
Weinstein, 2003, Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women., Osteoporos Int, 14, 814, 10.1007/s00198-003-1434-z
Sarkar, 2004, Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk., J Bone Miner Res, 19, 394, 10.1359/JBMR.0301243
Reginster, 2004, Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk., Bone, 34, 344, 10.1016/j.bone.2003.10.004
Sarkar, 2002, Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy., J Bone Miner Res, 17, 1, 10.1359/jbmr.2002.17.1.1
Riggs, 2002, Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density., J Bone Miner Res, 17, 11, 10.1359/jbmr.2002.17.1.11
Maricic, 2002, Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis., Arch Intern Med, 162, 1140, 10.1001/archinte.162.10.1140
Qu, 2005, The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial., Curr Med Res Opin, 21, 1955, 10.1185/030079905X75032
Johnell, 2004, Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study., J Bone Miner Res, 19, 764, 10.1359/jbmr.040211
Antoniucci, 2005, Vitamin D insufficiency does not affect bone mineral density response to raloxifene., J Clin Endocrinol Metab, 90, 4566, 10.1210/jc.2005-0290
Kanis, 2003, Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene evaluation trial., Bone, 33, 293, 10.1016/S8756-3282(03)00200-X
Ensrud, 2008, Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart trial., J Bone Miner Res, 23, 112, 10.1359/jbmr.070904
Siris, 2002, Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study., Osteoporosos Int, 13, 907, 10.1007/s001980200125
Delmas, 2003, Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial., Bone, 33, 522, 10.1016/S8756-3282(03)00241-2
Seeman, 2006, Anti-vertebral fracture efficacy of raloxifene: a meta-analysis., Osteoporos Int, 17, 313, 10.1007/s00198-005-2030-1
Cauley, 2001, Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial., Breast Cancer Res Treat, 65, 125, 10.1023/A:1006478317173
Martino, 2004, Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene., J Natl Cancer Inst, 96, 1751, 10.1093/jnci/djh319
Lippman, 2006, Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk., Clin Cancer Res, 12, 5242, 10.1158/1078-0432.CCR-06-0688
Freedman, 2001, Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo., J Natl Cancer Inst, 93, 51, 10.1093/jnci/93.1.51
Jackson, 2003, Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women., Am J Obstet Gynecol, 188, 389, 10.1067/mob.2003.21
Cirpan, 2006, Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients?, Eur J Gynaecol Oncol, 27, 177
Lasco, 2006, Effect of long-term treatment with raloxifene on mammary density in postmenopausal women., Menopause, 13, 787, 10.1097/01.gme.0000233493.20712.ad
Martino, 2005, Safety assessment of raloxifene over eight years in a clinical trial setting., Curr Med Res Opin, 21, 1441, 10.1185/030079905X61839
Davies, 1999, Adverse events reported by postmenopausal women in controlled trials with raloxifene., Obstet Gynecol, 93, 558
Duvernoy, 2005, Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene., Menopause, 12, 444, 10.1097/01.GME.0000151653.02620.89
Grady, 2004, Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation., Obstet Gynecol, 104, 837, 10.1097/01.AOG.0000137349.79204.b8
Cohen, 2000, Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials., Maturitas, 34, 65, 10.1016/S0378-5122(99)00090-0
Boss, 1997, Effects of raloxifene hydrochloride on the endometrium of postmenopausal women., Am J Obstet Gynecol, 177, 1458, 10.1016/S0002-9378(97)70091-7
Davies, 1999, Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women., Menopause, 6, 188
Cohen, 2000, Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60., Obstet Gynecol, 95, 104
Goldstein, 2000, A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium., Obstet Gynecol, 95, 95
Neven, 2003, A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate., BJOG, 110, 157, 10.1046/j.1471-0528.2003.02252.x
Neven, 2004, Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study., Obstet Gynecol, 103, 881, 10.1097/01.AOG.0000124850.56600.b8
Goldstein, 2001, The effect of SERMs on the endometrium., Ann N Y Acad Sci, 949, 237, 10.1111/j.1749-6632.2001.tb04027.x
Demichele, 2005, Effect of raloxifene on endometrial cancer risk in a population-based, case control study., J Clin Oncol, 23, 16S, 10.1200/jco.2005.23.16_suppl.5001
Neven, 2002, The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women., Gynecol Oncol, 85, 388, 10.1006/gyno.2001.6578
Goldstein, 2001, Raloxifene effect on frequency of surgery for pelvic floor relaxation., Obstet Gynecol, 98, 91
Goldstein, 2005, Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen., Menopause, 12, 160, 10.1097/00042192-200512020-00010
Waetjen, 2004, Effect of raloxifene on urinary incontinence: a randomized controlled trial., Obstet Gynecol, 103, 261, 10.1097/01.AOG.0000109429.67671.d1
Goldstein, 2002, An update on non-uterine gynaecological effects on raloxifene., Eur J Cancer, 38, S65, 10.1016/S0959-8049(02)00291-5
Walsh, 2001, Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women., Am J Cardiol, 88, 825, 10.1016/S0002-9149(01)01865-3
Walsh, 2001, The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors., Ann N Y Acad Sci, 949, 163, 10.1111/j.1749-6632.2001.tb04015.x
Walsh, 2000, The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial., J Clin Endocrinol Metab, 85, 214
Walsh, 1998, Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women., JAMA, 279, 1445, 10.1001/jama.279.18.1445
Nickelsen, 2001, Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study., Climacteric, 4, 320, 10.1080/cmt.4.4.320.331
Ensrud, 2006, Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis., Am J Cardiol, 97, 520, 10.1016/j.amjcard.2005.09.083
Barrett-Connor, 2002, Raloxifene and risk of stroke among high-risk women in the Multiple Outcomes of Raloxifene Evaluation trial., Circulation, 106, II
Keech, 2005, Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial., Curr Med Res Opin, 21, 135, 10.1185/030079904X18045
Yaffe, 2001, Cognitive function in postmenopausal women treated with raloxifene., N Engl J Med, 344, 1207, 10.1056/NEJM200104193441604
Yaffe, 2005, Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial., Am J Psychiatry, 162, 683, 10.1176/appi.ajp.162.4.683
Munster, 2006, Arzoxifene: the development and clinical outcome of an ideal SERM., Expert Opin Investig Drugs, 15, 317, 10.1517/13543784.15.3.317
Sporn, 2004, Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer., Clin Cancer Res, 10, 5313, 10.1158/1078-0432.CCR-04-1377
Fabian, 2004, Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator., Clin Cancer Res, 10, 5403, 10.1158/1078-0432.CCR-04-0171
McMeekin, 2003, A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer., Gynecol Oncol, 90, 64, 10.1016/S0090-8258(03)00203-8
Singh, 2001, Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders., Med Res Rev, 21, 302, 10.1002/med.1011
Ravn, 2006, What can be learned from the levormeloxifene experience?, Acta Obstet Gynecol Scand, 85, 135, 10.1080/00016340500345691
Warming, 2003, Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal., Maturitas, 44, 189, 10.1016/S0378-5122(02)00342-0
Goldstein, 2002, Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study., Am J Obstet Gynecol, 187, 521, 10.1067/mob.2002.123938
Christgau, 2004, Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM)., Menopause, 11, 508, 10.1097/01.WCB.0000121484.18437.98
Labrie, 2004, Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer., J Clin Oncol, 22, 864, 10.1200/JCO.2004.05.122
Gardner, 2006, Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women., J Clin Pharmacol, 46, 52, 10.1177/0091270005283280
Gennari, 2006, Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis., Drugs Today (Barc), 42, 355, 10.1358/dot.2006.42.6.973583
Gennari, 2006, Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis., Expert Opin Investig Drugs, 15, 1091, 10.1517/13543784.15.9.1091
McClung, 2006, Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene., Menopause, 13, 377, 10.1097/01.gme.0000188736.69617.4f
Goldstein, 2006, Not all selective estrogen response modulators are created equal: update on lasofoxifene., Int J Gynecol Cancer, 16, 504, 10.1111/j.1525-1438.2006.00681.x
Cotreau, 2002, Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women., J Clin Pharmacol, 42, 157, 10.1177/00912700222011193
Sadler, 2006, Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus., Endocr Relat Cancer, 13, 863, 10.1677/erc.1.01170
Komm, 2005, Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity., Endocrinology, 146, 3999, 10.1210/en.2005-0030
Ronkin, 2005, Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women., Obstet Gynecol, 105, 1397, 10.1097/01.AOG.0000163253.27610.b9
Vogelvang, 2005, HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women., J Thromb Haemost, 3, 1090, 10.1111/j.1538-7836.2005.01306.x
Vogelvang, 2005, The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women., Am J Obstet Gynecol, 193, 1384, 10.1016/j.ajog.2005.02.083
Vogelvang, 2004, Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women., Menopause, 11, 110, 10.1097/01.GME.0000097740.18446.77
Buzdar, 2006, Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer., Ann Pharmacother, 40, 1572, 10.1345/aph.1G401
Howell, 2006, Pure oestrogen antagonists for the treatment of advanced breast cancer., Endocr Relat Cancer, 13, 689, 10.1677/erc.1.00846
Howell, 2006, Fulvestrant (‘Faslodex’): current and future role in breast cancer management., Crit Rev Oncol Hematol, 57, 265, 10.1016/j.critrevonc.2005.08.001